The Ann & Robert H. Lurie Children’s Hospital of Chicago Named First Qualified Treatment Center for Zevaskyn in RDEB
The Ann & Robert H. Lurie Children’s Hospital of Chicago is now activated as the first Qualified Treatment Center (QTC) for the use of Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets to treat wounds associated with recessive dystrophic epidermolysis bullosa (RDEB).